1. Home
  2. TWLO vs ILMN Comparison

TWLO vs ILMN Comparison

Compare TWLO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twilio Inc.

TWLO

Twilio Inc.

HOLD

Current Price

$192.32

Market Cap

31.8B

Sector

Technology

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$191.31

Market Cap

26.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWLO
ILMN
Founded
2008
1998
Country
United States
United States
Employees
5587
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8B
26.7B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
TWLO
ILMN
Price
$192.32
$191.31
Analyst Decision
Buy
Hold
Analyst Count
24
17
Target Price
$151.54
$124.24
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
04-30-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
170.87
EPS
N/A
0.87
Revenue
N/A
$4,343,000,000.00
Revenue This Year
$14.44
$6.47
Revenue Next Year
$8.21
$5.58
P/E Ratio
$526.76
$223.09
Revenue Growth
N/A
N/A
52 Week Low
$91.84
$88.00
52 Week High
$238.48
$199.14

Technical Indicators

Market Signals
Indicator
TWLO
ILMN
Relative Strength Index (RSI) 45.17 59.50
Support Level $179.78 $116.54
Resistance Level $202.50 $196.66
Average True Range (ATR) 10.13 6.78
MACD -2.89 -0.75
Stochastic Oscillator 31.15 67.18

Price Performance

Historical Comparison
TWLO
ILMN

About TWLO Twilio Inc.

Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: